Q-omics provides the consensus-scored LILRA6 profile across patient tissues and cancer cell-line models. LILRA6 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, LILRA6 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, LILRA6 RNA expression shows 19,324 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where LILRA6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LILRA6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LILRA6 survival associations across molecular data types. LILRA6 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LILRA6 RNA expression–survival associations across cancer types. High LILRA6 expression shows unfavorable associations in ACC, LGG, LAML, STAD and GBM, but favorable associations in SKCM. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for LILRA6 RNA expression.
This table summarizes LILRA6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for LILRA6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LILRA6 shows lower tumor expression in LUAD and LUSC and higher tumor expression in KIRC, HNSC, KIRP and THCA. The KIRC box plot shows higher LILRA6 RNA expression in tumor versus normal tissue (log2 FC = +1.257, t-test p < 0.001).
This table shows molecular features associated with LILRA6 in patient tissues and cancer cell lines. In patient samples, LILRA6 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, LILRA6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
